AAMU
TGTX icon

Amundi Asset Management US’s TG Therapeutics TGTX Stock Holding History

Amundi Asset Management US’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$276K Sell
5,726
-5,874
-51% -$282K ﹤0.01% 1432
2020
Q4 		$603K Hold
11,600
– – ﹤0.01% 1266
2020
Q3 		$310K Buy
+11,600
New +$267K ﹤0.01% 1321

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Amundi Asset Management US's TGTX Position: Q1 2021 in Review

Amundi Asset Management US reduced its TG Therapeutics (TGTX) stake by 51% in Q1 2021, selling an estimated $282K and leaving 5,726 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Amundi Asset Management US first reported a position in TGTX in Q3 2020 and has held it in 3 quarters since. The position peaked at $603K in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

  • Amundi Asset Management US held 5,726 shares of TG Therapeutics worth $276K as of Q1 2021.
  • Amundi Asset Management US sold 5,874 TG Therapeutics shares in Q1 2021, an estimated $282K.
  • TG Therapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1432 holding.
  • Amundi Asset Management US first reported a position in TG Therapeutics in Q3 2020 and has held it in 3 quarters since.
  • Amundi Asset Management US's TG Therapeutics position peaked at $603K in Q4 2020.
  • 240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.